ORIC Pharmaceuticals Reports Inducement Grants

Biotech firm grants stock options and restricted stock units to new employee

Apr. 3, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

A highly polished, reflective metal trophy or award standing alone on a clean, white background, symbolizing the prestige and recognition of ORIC Pharmaceuticals' talent acquisition efforts.ORIC Pharmaceuticals' strategic equity incentives aim to attract top talent and align their interests with the company's long-term success.San Diego Today

ORIC Pharmaceuticals, a clinical-stage oncology company, announced that it has granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee who joined the company in March 2026. The inducement grants were approved by ORIC's Compensation Committee and granted as a material inducement to employment.

Why it matters

The announcement of these inducement grants provides insight into ORIC's strategy to attract and retain top talent as it continues to advance its pipeline of oncology treatments. Offering competitive equity compensation packages is a common practice in the biotech industry to incentivize new hires and align their interests with those of the company and its shareholders.

The details

The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date. Twenty-five percent of the shares subject to the stock options will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following three years. One-third of the restricted stock units will vest on each of the first three anniversaries of the grant date.

  • The grants were made on April 1, 2026.
  • The new employee joined ORIC in March 2026.

The players

ORIC Pharmaceuticals, Inc.

A clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

ORIC's Compensation Committee

The committee that approved the inducement grants as required by Nasdaq Rule 5635(c)(4).

Got photos? Submit your photos here. ›

The takeaway

The announcement of these inducement grants highlights ORIC's commitment to building a talented team as it continues to advance its pipeline of oncology treatments. Offering competitive equity compensation packages is a common practice in the biotech industry to attract and retain top talent.